Amarin Corporation Plc ((AMRN)) has held its Q3 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amarin Corporation’s recent earnings call painted a picture of cautious optimism. The company reported significant growth in U.S. market sales, bolstered by successful partnerships and strategic cost reductions. Despite these positive developments, challenges persist, particularly with declining revenues from the Rest of World markets and ongoing restructuring costs.
Increase in Total Net Revenue
The third quarter of 2025 saw Amarin Corporation’s total net revenue rise to $49.7 million, marking a 17% increase from the previous year. This growth was primarily attributed to higher sales in the U.S. market, showcasing the company’s strengthened domestic performance.
U.S. Market Performance
Amarin’s U.S. net product revenue surged to $40.9 million, reflecting a 34% increase. This impressive growth was driven by an increase in both net selling price and sales volume, highlighting the company’s effective market strategies and regained exclusivity with a major pharmacy benefit manager.
Successful Partnership with Recordati
The transition to a fully partnered commercial model in Europe, managed by Recordati, is progressing well. This partnership has maintained momentum and growth in demand across all commercialized European markets, indicating a successful strategic move by Amarin.
Cost Savings and Restructuring
Amarin achieved significant cost savings, reducing SG&A expenses by 47% compared to the previous year. This reduction underscores the benefits of the company’s organizational restructuring efforts, contributing to its financial health.
FDA Labeling Update on Fenofibrates
The FDA’s recent revision of fenofibrates labeling to include a statement on the lack of cardiovascular benefit is expected to shift clinical practices towards proven therapies like VASCEPA, potentially boosting its market position.
Decline in Rest of World Revenue
Despite the positive trends, Amarin faced a decline in Rest of World revenue, which fell to $3.6 million. This decline highlights the variability and challenges the company faces in these markets.
European Revenue Consistency
European product revenue remained stable at $4.1 million, consistent with the previous year. However, this stability contrasts with the significant growth seen in the U.S. market.
Ongoing Restructuring Costs
Amarin reported restructuring expenses of $9.4 million, contributing to an operating loss of $11.1 million. While these costs are expected to decrease in the future, they currently impact the company’s financial performance.
Forward-Looking Guidance
Looking ahead, Amarin Corporation remains focused on expanding VASCEPA’s market reach globally, with a strategic emphasis on cardiovascular risk reduction. The company anticipates achieving positive free cash flow by 2026, supported by its successful partnerships and operational cost savings. The FDA’s labeling update on fenofibrates is expected to further enhance VASCEPA’s market appeal.
In summary, Amarin Corporation’s earnings call revealed a positive outlook, driven by robust U.S. sales growth and strategic partnerships. While challenges remain, particularly in international markets, the company’s focus on cost reduction and market expansion positions it well for future success.